Viaderma Stock Performance
| VDRM Stock | USD 0.01 0.00 0.00% |
Viaderma holds a performance score of 8 on a scale of zero to a hundred. The entity has a beta of -1.03, which indicates a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Viaderma are expected to decrease slowly. On the other hand, during market turmoil, Viaderma is expected to outperform it slightly. Use Viaderma jensen alpha and the relationship between the value at risk and day typical price , to analyze future returns on Viaderma.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Viaderma are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of very fragile basic indicators, Viaderma displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Viaderma |
Viaderma Relative Risk vs. Return Landscape
If you would invest 0.60 in Viaderma on September 14, 2024 and sell it today you would earn a total of 0.30 from holding Viaderma or generate 50.0% return on investment over 90 days. Viaderma is currently generating 1.3462% in daily expected returns and assumes 12.6312% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Viaderma, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Viaderma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Viaderma's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Viaderma, and traders can use it to determine the average amount a Viaderma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1066
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | VDRM | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 12.63 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.35 actual daily | 26 74% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Viaderma is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Viaderma by adding it to a well-diversified portfolio.
Viaderma Fundamentals Growth
Viaderma Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Viaderma, and Viaderma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Viaderma Pink Sheet performance.
| Return On Asset | -0.91 | |||
| Operating Margin | (13.28) % | |||
| Current Valuation | 6.18 M | |||
| Shares Outstanding | 137.32 K | |||
| Price To Earning | 0.03 X | |||
| Price To Book | 0 X | |||
| Price To Sales | 2.01 X | |||
| Revenue | 44.69 K | |||
| EBITDA | (592.43 K) | |||
| Cash And Equivalents | 13.08 K | |||
| Debt To Equity | 20.90 % | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (167.36 K) | |||
| Earnings Per Share | 0.16 X | |||
| Total Asset | 426.56 K | |||
| Retained Earnings | (7.38 M) | |||
| Current Asset | 185 K | |||
| Current Liabilities | 630 K | |||
About Viaderma Performance
By examining Viaderma's fundamental ratios, stakeholders can obtain critical insights into Viaderma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Viaderma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
ViaDerma, Inc. operates as a specialty pharmaceutical company in the United States. ViaDerma, Inc. was incorporated in 2007 and is headquartered in Marina Del Rey, California. Viaderma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.Things to note about Viaderma performance evaluation
Checking the ongoing alerts about Viaderma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Viaderma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Viaderma is way too risky over 90 days horizon | |
| Viaderma has some characteristics of a very speculative penny stock | |
| Viaderma appears to be risky and price may revert if volatility continues | |
| Viaderma has high likelihood to experience some financial distress in the next 2 years | |
| The company has a current ratio of 0.28, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Viaderma until it has trouble settling it off, either with new capital or with free cash flow. So, Viaderma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Viaderma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Viaderma to invest in growth at high rates of return. When we think about Viaderma's use of debt, we should always consider it together with cash and equity. | |
| Viaderma reported the previous year's revenue of 44.69 K. Net Loss for the year was (1.52 M) with profit before overhead, payroll, taxes, and interest of 37.63 K. | |
| Viaderma currently holds about 13.08 K in cash with (167.36 K) of positive cash flow from operations. |
- Analyzing Viaderma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Viaderma's stock is overvalued or undervalued compared to its peers.
- Examining Viaderma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Viaderma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Viaderma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Viaderma's pink sheet. These opinions can provide insight into Viaderma's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Viaderma Pink Sheet
Viaderma financial ratios help investors to determine whether Viaderma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Viaderma with respect to the benefits of owning Viaderma security.